Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants.

The Journal of infectious diseases - 1 Sept 2004

DeVincenzo John P, Hall Caroline B, Kimberlin David W, Sánchez Pablo J, Rodriguez William J, Jantausch Barbara A, Corey Lawrence, Kahn Jeffrey S, Englund Janet A, Suzich JoAnn A, Palmer-Hill Frances J, Branco Luis, Johnson Syd, Patel Nita K, Piazza Franco M

Abstract excerpt

Premature infants and those with chronic lung disease or congenital heart disease are at high risk of severe respiratory syncytial virus (RSV) disease. Palivizumab (Synagis), a humanized anti-RSV monoclonal antibody, has been used extensively since 1998 to prevent severe RSV disease in high-risk infants. To monitor for possible palivizumab-resistant mutants, an immunofluorescence binding assay that predicts...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Viral

Share to Fluorescent Antibody Technique

Share to Hospitalization

Share to Neutralization Tests

Share to Respiratory Syncytial Virus, Human

Share to Respiratory Syncytial Virus Infections

Source

Identifiers

PMID: 15295704
DOI: 10.1086/423213

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants.PMID 15295704Read ↗

Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis.Semantic proximity Read ↗

Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab.Semantic proximity Read ↗

Palivizumab‐Resistant Human Respiratory Syncytial Virus Infection in InfancySemantic proximity Read ↗

Neutralizing epitopes of RSV and palivizumab resistance in Japan.Semantic proximity Read ↗

Reverse genetics systems for contemporary isolates of respiratory syncytial virus enable rapid evaluation of antibody escape mutants.Semantic proximity Read ↗

Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization.Semantic proximity Read ↗

Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.Semantic proximity Read ↗

Use of palivizumab and infection control measures to control an outbreak of respiratory syncytial virus in a neonatal intensive care unit confirmed by real-time polymerase chain reaction.Semantic proximity Read ↗

Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats.Semantic proximity Read ↗

Variable resistance to palivizumab in cotton rats by respiratory syncytial virus mutants.Semantic proximity Read ↗

Cell fusion assay by expression of respiratory syncytial virus (RSV) fusion protein to analyze the mutation of palivizumab-resistant strains.Semantic proximity Read ↗

In Vivo Selection of Respiratory Syncytial Viruses Resistant to PalivizumabSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.